Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride and abiraterone acetate in men with castration-resistant prostate cancer patients with symptomatic bone metastases.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. e16546-e16546 ◽  
Author(s):  
Luke T. Nordquist ◽  
Neal D. Shore
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Phase Ii Study ◽  
Abiraterone Acetate ◽  
Castration Resistant Prostate Cancer ◽  
Concurrent Administration ◽  
Open Label ◽  
Castration Resistant ◽  
Open Label Phase

scholarly journals Re‐treatment with radium‐223: 2‐year follow‐up from an international, open‐label, phase 1/2 study in patients with castration‐resistant prostate cancer and bone metastases

The Prostate ◽  
2019 ◽  
Vol 79 (14) ◽  
pp. 1683-1691 ◽  
Author(s):  
Oliver Sartor ◽  
Daniel Heinrich ◽  
Neil Mariados ◽  
Maria José Méndez Vidal ◽  
Daniel Keizman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Phase 1 ◽  
Castration Resistant Prostate Cancer ◽  
Open Label ◽  
Castration Resistant ◽  
Radium 223 ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document